215 related articles for article (PubMed ID: 36344621)
1. Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations.
Frenois-Veyrat G; Gallardo F; Gorgé O; Marcheteau E; Ferraris O; Baidaliuk A; Favier AL; Enfroy C; Holy X; Lourenco J; Khoury R; Nolent F; Grosenbach DW; Hruby DE; Ferrier A; Iseni F; Simon-Loriere E; Tournier JN
Nat Microbiol; 2022 Dec; 7(12):1951-1955. PubMed ID: 36344621
[TBL] [Abstract][Full Text] [Related]
2. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
DeLaurentis CE; Kiser J; Zucker J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo efficacy of tecovirimat against a recently emerged 2022 monkeypox virus isolate.
Warner BM; Klassen L; Sloan A; Deschambault Y; Soule G; Banadyga L; Cao J; Strong JE; Kobasa D; Safronetz D
Sci Transl Med; 2022 Nov; 14(673):eade7646. PubMed ID: 36318038
[TBL] [Abstract][Full Text] [Related]
4. Clinical considerations on monkeypox antiviral medications: An overview.
Pourkarim F; Entezari-Maleki T
Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
[TBL] [Abstract][Full Text] [Related]
5. Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme.
Bourner J; Redji Mbrenga FD; Malaka CN; Dunning J; Rojek A; Fandema E; Horby P; Boum Y; Nakouné E; Olliaro P
PLoS One; 2024; 19(5):e0278957. PubMed ID: 38722986
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat.
Nunes DDS; Higa LM; Oliveira RL; da Costa LC; Bomfim LM; Gonçalves CCA; Mariani D; Hruby DE; Voloch CM; Castiñeiras TMPP; Tanuri A; Damaso CR
Mem Inst Oswaldo Cruz; 2023; 118():e230056. PubMed ID: 37436275
[TBL] [Abstract][Full Text] [Related]
7. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
[TBL] [Abstract][Full Text] [Related]
8. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review.
Shamim MA; Padhi BK; Satapathy P; Veeramachaneni SD; Chatterjee C; Tripathy S; Akhtar N; Pradhan A; Dwivedi P; Mohanty A; Rodriguez-Morales AJ; Sah R; Al-Tammemi AB; Al-Tawfiq JA; Nowrouzi-Kia B; Chattu VK
Int J Infect Dis; 2023 Feb; 127():150-161. PubMed ID: 36470502
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
[TBL] [Abstract][Full Text] [Related]
11. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
[TBL] [Abstract][Full Text] [Related]
12. Monkeypox: A re-emerging disease.
Kaur N; Dabar J; Bassi P
Indian J Pharmacol; 2024 Mar; 56(2):129-135. PubMed ID: 38687317
[TBL] [Abstract][Full Text] [Related]
13. Identification of
Chiem K; Nogales A; Lorenzo M; Morales Vasquez D; Xiang Y; Gupta YK; Blasco R; de la Torre JC; Martínez-Sobrido L
Microbiol Spectr; 2023 Aug; 11(4):e0474522. PubMed ID: 37278625
[TBL] [Abstract][Full Text] [Related]
14. Monkeypox Virus (MPXV) Infection: A Review.
Kumari R; Arya P; Yadav SP; Mishra RC; Yadav JP
Infect Disord Drug Targets; 2024; 24(4):76-82. PubMed ID: 38243966
[TBL] [Abstract][Full Text] [Related]
15. Potential therapeutic targets for Mpox: the evidence to date.
Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K
Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
17. Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques.
Russo AT; Grosenbach DW; Brasel TL; Baker RO; Cawthon AG; Reynolds E; Bailey T; Kuehl PJ; Sugita V; Agans K; Hruby DE
J Infect Dis; 2018 Sep; 218(9):1490-1499. PubMed ID: 29982575
[TBL] [Abstract][Full Text] [Related]
18. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.
Berhanu A; Prigge JT; Silvera PM; Honeychurch KM; Hruby DE; Grosenbach DW
Antimicrob Agents Chemother; 2015 Jul; 59(7):4296-300. PubMed ID: 25896687
[TBL] [Abstract][Full Text] [Related]
19. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models.
Cinatl J; Bechtel M; Reus P; Ott M; Rothweiler F; Michaelis M; Ciesek S; Bojkova D
J Med Virol; 2024 Jan; 96(1):e29354. PubMed ID: 38180134
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in the Prevention and Management of Monkeypox Viral Infection in Humans.
Gujjar P; Chaudhay R; Verma I; Bansal N; Gupta S; Bansal S
Curr Drug Targets; 2023; 24(13):1032-1045. PubMed ID: 37842888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
